Ignite Creation Date:
2024-05-06 @ 3:06 AM
Last Modification Date:
2024-10-26 @ 11:28 AM
Study NCT ID:
NCT02201992
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2014-07-21
Brief Title:
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations An ALCHEMIST Treatment Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Organization:
Eastern Cooperative Oncology Group
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Stage IIIA Non-Small Cell Lung Cancer AJCC v7 |
| ALK Gene Rearrangement |
| ALK Gene Translocation |
| ALK Positive |
| Stage IB Non-Small Cell Lung Carcinoma AJCC v7 |
| Stage II Non-Small Cell Lung Cancer AJCC v7 |
| Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 |
| Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 |
Keywords: